CD19 Antibody, anti-mouse, REAfinity™
Synonyms: B4
RECOMBINANT EXTENDED VALIDATION
Bioz Star95/100 Bioz rating
59 Citations8 Images
Clone:
REA749 | 6D5
Type of antibody:
Primary antibodies, Recombinant antibodies
Isotype:
recombinant human IgG1
Applications:
FC, MICS, 3D-IF, IF, IHC Glossary
External link icon
Quality Assurance Certified ProductSatisfaction
guaranteed
more »
Select a conjugate:

Related products for CD19 Antibody, anti-mouse, REAfinity™

Flow cytometry applications
APC
APC-Vio 770
Biotin
PE
PE-Vio 615
PE-Vio 770
PerCP-Vio 700
Vio Bright B515
Vio Bright R720
VioBlue
Recommended dilution:
1:50
Remark:
The antibody is suited for staining of formaldehyde-fixed cells.
Data source:
Miltenyi Biotec
Conjugate:
APC
Used products:
130-112-036, 130-111-884
Description:
Splenocytes from BALB/c mice were stained with CD19 antibodies or with the corresponding REA Control antibodies (left images) as well as with CD45R (B220) antibodies and analyzed by flow cytometry using the MACSQuant® Analyzer. Cell debris and dead cells were excluded from the analysis based on scatter signals and propidium iodide fluorescence or 4',6-diamidino-2-phenylindole (DAPI) fluorescence, as in the case of tandem conjugates.

Application imageView details view details

Application imageView details view details
MICS (MACSima Imaging Cyclic Staining) applications
APC
PE
Fixation:
frozen – Acetone
Species tested:
mouse
Recommended dilution:
1:50
Data source:
Miltenyi Biotec
Compatible applications:
IF, IHC
Conjugate:
APC
Used products:
130-112-036, 130-111-884
Testing grade:
Fixation:
frozen – PFA
Species tested:
mouse
Recommended dilution:
1:50
Data source:
Miltenyi Biotec
Compatible applications:
IF, IHC
Conjugate:
APC
Used products:
130-112-036, 130-111-884
Testing grade:
3D-Immunofluorescence applications
Vio 780
Vio G570
Vio R667
Tissue clearing:
MACS® Clearing Kit
Fixation:
PFA
Species tested:
mouse
Tissue used:
lymph node
Recommended dilution:
1:50
Data source:
Miltenyi Biotec
Compatible applications:
IF, IHC
Conjugate:
Vio 780
Used products:
130-135-520
Protocols:
Immunostaining and clearing of mouse lymph nodes for 3D imaging analysis.
Description:
3D-immunofluorescence analysis of mouse lymphnodes fixed with 4% PFA and subjected to whole-mount immunostaining with CD19 Antibody, mouse, Vio® 780 (magenta). The sample was processed and optically cleared using the MACS® Clearing Kit and imaged with an UltraMicroscope Blaze light sheet instrument. Sample detail image of lymphnodes (A), overview of lymphnode (B). Scale bars: 100 µm (A), 500 µm (B).

Application imageView details view details

Application imageView details view details
Extended validation for CD19 Antibody, anti-mouse, REAfinity™
Specificity
Epitope competition assay

In order to compare the epitope specificity of an antibody, the clone being used is compared with other known clones recognizing the same antigen in a competition assay.

Other clones
Overlap in epitope recognition with REA749
6D5
high
1D3
high
MB19-1
high

Cells were incubated with an excess of purified unconjugated CD19 (REA749) antibody followed by staining with fluorochrome-conjugated antibodies from other known clones targeting the same antigen. Fluorescence intensity was then used to assess epitope overlap: a minimal or absent signal indicated high epitope overlap, an intermediate signal suggested partial overlap, and a strong signal reflected low overlap.

Sensitivity
Performance comparison

Selected fluorochrome conjugated antibodies from Miltenyi Biotec were compared to commercially available hybridoma clones in flow cytometry analysis.

Extended-Validation detailed information image
Extended-Validation detailed information image
Extended-Validation detailed information image
Extended-Validation detailed information image
Extended-Validation detailed information image
Extended-Validation detailed information image
Extended-Validation detailed information image

Flow cytometric comparison of different clones for CD19. C57BL6/6 splenocytes were stained with CD19 antibodies and with a suitable counterstaining. As a control, CD19 antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.

Extended-Validation detailed information image

Flow cytometric comparison of different clones for CD19 shown as histograms

Fixation data

To provide an indication on how an antibody performs after fixation of cells, in-house data on staining results before and after fixation with 3.7% formaldehyde using Miltenyi Biotec antibodies are provided. Different experimental settings may lead to different results.

No fixation
Extended-Validation detailed information image
Post fixation
Extended-Validation detailed information image

Comparison of staining pattern on non-fixed and fixed cells using CD19 (REA749). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.

Specifications for CD19 Antibody, anti-mouse, REAfinity™
Overview

Clone REA749 recognizes the mouse CD19 antigen, a type I transmembrane glycoprotein expressed on B cells throughout their development from the early pro–B cell through the mature B cell stages. Its expression is down-regulated during terminal differentiation to plasma cells. CD19 associates with complement receptor CD21 and with CD81 on the cell surface of mature B cells, thereby forming a multi-molecular complex which signals synergistically to membrane IgM. It is also expressed on follicular dendritic cells and peritoneal mast cells.

Additional information: Clone REA749 displays negligible binding to Fc receptors.

Alternative names

B4

Detailed product information

Technical specifications

Clone
REA749
Clonality
monoclonal
Isotype
recombinant human IgG1
Isotype control
REA Control Antibody, human IgG1
Host
human cell line
Type of antibody
Primary antibodies, Recombinant antibodies
Species reactivity
mouse
Antigen
CD19
Molecular mass of antigen [kDa]
58
Distribution of antigen
B cells, dendritic cells
Entrez Gene ID
RRID
AB_2751063, AB_2655823, AB_2655829, AB_2655822, AB_2655833, AB_2655834, AB_2655835, AB_2655831, AB_2655830, AB_2655827, AB_2655837, AB_2655836, AB_2655826, AB_2655832, AB_2751057, AB_2655828, AB_2921892, AB_2655824, AB_2655825

Recombinant antibodies at Miltenyi Biotec

As an innovation-powered company with a commitment to quality and excellence, Miltenyi Biotec applies cutting-edge methods to discover and develop newer and better antibodies to satisfy both market demand and regulatory requirements.

The Miltenyi way of generating best-in-class antibodies and antibody conjugates

At Miltenyi Biotec, we opt for recombinant antibodies, which enable sequence verification and optimization for lot-to-lot consistency, making them superior to hybridoma-based antibodies.

Infusing our unique expertise

Recombinants are the result of combining genetic material from different immunized animals, and using display technologies to screen in-house antibody libraries for the best antibodies. Additional analyses on existing hybridoma-based antibodies can also give rise to sequences contributing to novel recombinants.

Maximizing value for your research

By further re-engineering these antibody sequences, we can precisely control their properties to achieve the following benefits:

reduce undesirable binding to Fc gamma receptors,

  • eliminate destabilizing amino acid motifs,
  • increase specific bonding affinity for stronger, more accurate targeting, and
  • optimize fluorochrome conjugation for brighter and clearer signals.

In a final step, by synthesizing and cloning the resulting gene sequence, we achieve an expression vector that develops a cell line, which in turn produces a special recombinant antibody.

Better science with quality antibodies

Already in 2015, 100 of the world’s leading scientists collectively called for better standards and reproducibility in antibody production, proposing recombinant antibodies to circumvent variability (Baker, M. Reproducibility crisis: Blame it on the antibodies. Nature 521, 274–276 (2015). https://doi.org/10.1038/521274a). Moreover, by applying reverse engineering, which is encouraged by the EU Directive 2016/943 r, Miltenyi Biotec acts “[i]n the interest of innovation and fostering competition…” (§16).

Resources for CD19 Antibody, anti-mouse, REAfinity™
Documents and Protocols
Certificates

To access a Certificate of Analysis (CoA) follow the link below and enter the specific lot of your product.

Get certificate

Should you wish to request additional documentation, such as a Safety Data Sheet (SDS) in other languages than English or Swedish, an SDS-replacement document, or a Certificate of Origin (CoO), please direct your inquiry to your local technical support team.

Contact technical support

You have previously chosen International as your location.
What do you want to do?